Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment
Background and Aims: Treatments for ulcerative colitis (UC) differ in safety, efficacy, and route of administration; patient preferences for treatment attributes should be considered in treatment decisions. No study to date has explored patient preferences for moderate-to-severe UC treatment in Midd...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Gastro Hep Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772572323001619 |
| _version_ | 1797295768726405120 |
|---|---|
| author | Othman AlHarbi Niazy Abu Farsakh Sameer Al-Awadhi Talal Al-Taweel Inas Mikhail Faisal Batwa Khalil Bedran Dilara Balkan Levent Mert Gunay Joseph C. Cappelleri Marco Boeri Colton Leach Sara Habjoka Mahmoud Mosli |
| author_facet | Othman AlHarbi Niazy Abu Farsakh Sameer Al-Awadhi Talal Al-Taweel Inas Mikhail Faisal Batwa Khalil Bedran Dilara Balkan Levent Mert Gunay Joseph C. Cappelleri Marco Boeri Colton Leach Sara Habjoka Mahmoud Mosli |
| author_sort | Othman AlHarbi |
| collection | DOAJ |
| description | Background and Aims: Treatments for ulcerative colitis (UC) differ in safety, efficacy, and route of administration; patient preferences for treatment attributes should be considered in treatment decisions. No study to date has explored patient preferences for moderate-to-severe UC treatment in Middle Eastern countries. Methods: A discrete-choice experiment aimed to quantify treatment preferences in patients with moderate-to-severe UC in 5 Middle Eastern countries (Saudi Arabia, Kuwait, Jordan, the United Arab Emirates, and Lebanon). Respondents chose between experimentally designed profiles for hypothetical UC treatments with varying efficacy (time until UC symptoms improve and chance of UC symptom control after 1 year), side effects (annual risk of serious infection, 5-year risk of malignancy), mode and frequency of administration, and need for occasional steroid use. A random-parameters logit model was used to estimate preference weights for these attributes, from which conditional relative importance estimates and maximum acceptable increases in risks of serious infection and malignancy were derived. Results: Among 365 adults with moderate-to-severe UC who completed the survey (mean age, 36 years; 50% female), 5-year risk of malignancy and symptom control after 1 year had the greatest conditional relative importance. Respondents were generally willing to accept statistically significant increases in annual risk of serious infection and 5-year risk of malignancy in exchange for better efficacy, changes in mode of administration and dosing schedule, and avoiding occasional steroid use. Conclusion: Of the attributes evaluated, individuals with UC in Middle Eastern countries most value avoiding 5-year risk of malignancy and a higher probability of symptom control, on average. |
| first_indexed | 2024-03-07T21:52:44Z |
| format | Article |
| id | doaj.art-caffa4965ef9401f9423f7161986b562 |
| institution | Directory Open Access Journal |
| issn | 2772-5723 |
| language | English |
| last_indexed | 2024-03-07T21:52:44Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gastro Hep Advances |
| spelling | doaj.art-caffa4965ef9401f9423f7161986b5622024-02-25T04:36:41ZengElsevierGastro Hep Advances2772-57232024-01-0132190200Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice ExperimentOthman AlHarbi0Niazy Abu Farsakh1Sameer Al-Awadhi2Talal Al-Taweel3Inas Mikhail4Faisal Batwa5Khalil Bedran6Dilara Balkan7Levent Mert Gunay8Joseph C. Cappelleri9Marco Boeri10Colton Leach11Sara Habjoka12Mahmoud Mosli13Department of Medicine, College of Medicine, King Saud University, King Saud University Medical City, Riyadh, Saudi ArabiaGastroenterology Unit, King Abdullah University Hospital, Irbed, JordanRashid Hospital, Dubai, United Arab EmiratesDivision of Gastroenterology, Department of Internal Medicine, Jaber Al-Ahmad Hospital, Kuwait City, KuwaitSheikh Shakhbout Medical City, Adu Dhabi, United Arab EmiratesKing Saud Bin Abdulaziz University of Health Sciences, Jeddah, Saudi ArabiaGastroenterology Division, Saint George Hospital University Medical Center (SGHUMC), Beirut, LebanonPfizer Gulf FZ LLC, Dubai, United Arab EmiratesPfizer PFE Ilaclari, Istanbul, TurkeyPfizer Inc., New York, New YorkRTI Health Solutions, Health Preference Assessment, Belfast, UK; Queen’s University of Belfast, School of Medicine, Belfast, UK; Correspondence: Address correspondence to: Marco Boeri, PhD, RTI Health Solutions, 123B Forsyth House, Cromac Square, Belfast BT2 8LA, UK.RTI Health Solutions, Health Preference Assessment, Research Triangle Park, North CarolinaPfizer Gulf FZ LLC, Dubai, United Arab EmiratesDepartment of Medicine, King Abdulaziz University, Jeddah, Saudi ArabiaBackground and Aims: Treatments for ulcerative colitis (UC) differ in safety, efficacy, and route of administration; patient preferences for treatment attributes should be considered in treatment decisions. No study to date has explored patient preferences for moderate-to-severe UC treatment in Middle Eastern countries. Methods: A discrete-choice experiment aimed to quantify treatment preferences in patients with moderate-to-severe UC in 5 Middle Eastern countries (Saudi Arabia, Kuwait, Jordan, the United Arab Emirates, and Lebanon). Respondents chose between experimentally designed profiles for hypothetical UC treatments with varying efficacy (time until UC symptoms improve and chance of UC symptom control after 1 year), side effects (annual risk of serious infection, 5-year risk of malignancy), mode and frequency of administration, and need for occasional steroid use. A random-parameters logit model was used to estimate preference weights for these attributes, from which conditional relative importance estimates and maximum acceptable increases in risks of serious infection and malignancy were derived. Results: Among 365 adults with moderate-to-severe UC who completed the survey (mean age, 36 years; 50% female), 5-year risk of malignancy and symptom control after 1 year had the greatest conditional relative importance. Respondents were generally willing to accept statistically significant increases in annual risk of serious infection and 5-year risk of malignancy in exchange for better efficacy, changes in mode of administration and dosing schedule, and avoiding occasional steroid use. Conclusion: Of the attributes evaluated, individuals with UC in Middle Eastern countries most value avoiding 5-year risk of malignancy and a higher probability of symptom control, on average.http://www.sciencedirect.com/science/article/pii/S2772572323001619Discrete ChoicePreferenceUlcerative ColitisMiddle East |
| spellingShingle | Othman AlHarbi Niazy Abu Farsakh Sameer Al-Awadhi Talal Al-Taweel Inas Mikhail Faisal Batwa Khalil Bedran Dilara Balkan Levent Mert Gunay Joseph C. Cappelleri Marco Boeri Colton Leach Sara Habjoka Mahmoud Mosli Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment Gastro Hep Advances Discrete Choice Preference Ulcerative Colitis Middle East |
| title | Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment |
| title_full | Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment |
| title_fullStr | Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment |
| title_full_unstemmed | Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment |
| title_short | Patient Preferences for Ulcerative Colitis Treatment in the Middle East Region: A Discrete-Choice Experiment |
| title_sort | patient preferences for ulcerative colitis treatment in the middle east region a discrete choice experiment |
| topic | Discrete Choice Preference Ulcerative Colitis Middle East |
| url | http://www.sciencedirect.com/science/article/pii/S2772572323001619 |
| work_keys_str_mv | AT othmanalharbi patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT niazyabufarsakh patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT sameeralawadhi patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT talalaltaweel patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT inasmikhail patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT faisalbatwa patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT khalilbedran patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT dilarabalkan patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT leventmertgunay patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT josephccappelleri patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT marcoboeri patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT coltonleach patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT sarahabjoka patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment AT mahmoudmosli patientpreferencesforulcerativecolitistreatmentinthemiddleeastregionadiscretechoiceexperiment |